Atypical Parkinsonian syndromes are a subset of progressive neurodegenerative disorders that present with signs of Parkinson's disease. However, due to multisystem degeneration, the atypical Parkinsonian syndromes have additional symptoms that are often referred to as Parkinson-plus syndromes. The most well-studied subsets include progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD), and Lewy body dementia. Specifically, progressive supranuclear palsy is a tauopathy neurodegenerative disorder that presents with parkinsonism symptoms along with postural instability, vertical saccade, and vertical gaze palsy. Here, we present a case of PSP and provide a brief review of the literature.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630753 | PMC |
| http://dx.doi.org/10.1016/j.radcr.2023.09.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical trial eligibility in PSP: Population representativeness and potential criteria adjustment based on PSP-NET findings.
Parkinsonism Relat Disord
December 2024
Neurology Unit and Neurobiorepository and Laboratory of Advanced Biological Markers, Department of Clinical and Experimental Sciences, University of Brescia, And Department of Continuity of Care and Frailty, ASST Spedali Civili Brescia Hospital, Brescia, Italy.
Background: Progressive Supranuclear Palsy (PSP) is a rare, heterogeneous neurodegenerative disease for which no treatment is currently available. In the context of clinical trials, the representativeness of the included patients is crucial for the generalizability of the results. Herein, we present results from a multicenter perspective study to identify the most restrictive criteria for patient selection and to assess the representativeness of eligible patients.
View Article and Find Full Text PDFA Short Progressive Supranuclear Palsy Quality of Life Scale: Data from the PSP-NET.
Mov Disord
December 2024
Center for Neurodegenerative Diseases (CEMAND), Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Baronissi, Italy.
Reply to: "A Short Progressive Supranuclear Palsy Quality of Life Scale: Data from the PSP-NET".
Mov Disord
December 2024
Department of Neurology, Hannover Medical School, Hannover, Germany.
FDA Boosts the Progressive Supranuclear Palsy Rating Scale!
Mov Disord
December 2024
CHDI Management, Inc. the company that manages the scientific activities of CHDI Foundation, Princeton, New Jersey, USA.
Splenomegaly and progressive neurologic involvement: Think about Niemann-Pick type C disease.
Pediatr Int
December 2024
Medical Faculty, Department of Pediatric Metabolism and Nutrition, Ege University, Izmir, Türkiye.
Background: Niemann-Pick type C (NPC) disease is a lysosomal storage disease with visceral organ involvement and neurological and psychiatric symptoms. This study presents the clinical and laboratory findings of NPC cases involving three novel variants.
Methods: The clinical and laboratory findings were reviewed retrospectively between February 2006 and December 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!